Based on CRISPR screen, data mining, and in vivo experiments, we identified and validated three genes (SMAD3, BIRC3, and SLC9A5) able to promote both BRAFi‐resistance and tumor growth. This evidence concerns the gene SMAD3 and neoplasm.